secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2024-12-26T23:59:59+00:00
Accession:  0001558370-24-016472
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics gets Nasdaq extension to June 16, 2025; stock transferred to Capital Market
--------------------------------------------------------------------------------

- Received 180-day extension until June 16, 2025 to meet $1.00 minimum bid price for continued listing.
- Common stock transferred from Nasdaq Global Market to Nasdaq Capital Market effective December 20, 2024.
- If bid price closes at $1.00 or more for 10 consecutive business days before deadline, compliance is achieved.
- Company may consider a reverse stock split to regain compliance; no assurance of success.
- Failure to comply by June 16, 2025 may lead to delisting, subject to appeal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837024016472/0001558370-24-016472-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837024016472/glyc-20241219x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-016472

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer